Company profile: Pulmonx
1.1 - Company Overview
Company description
- Provider of minimally invasive medical devices and technologies for diagnosing and treating pulmonary disorders, including the Zephyr Valve for severe emphysema to reduce hyperinflation and improve lung function without surgery, and the Chartis System, a bronchoscopy-based diagnostic tool measuring airflow and resistance to assess lung compartments for Zephyr Valve treatment.
Products and services
- Chartis System: Bronchoscopic diagnostic system measuring airflow/resistance, assessing lung compartments for treatment with Zephyr Valves
- Minimally-invasive Pulmonary Technologies: Clinical-grade devices/technologies for diagnosis and treatment of pulmonary disorders, focusing on non-surgical intervention
- Zephyr Valve: Minimally-invasive device treating severe emphysema, reducing hyperinflation and improving lung function without surgery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pulmonx
Oriel Therapeutics
HQ: United States
Website
- Description: Provider of specialty pharmaceutical solutions focused on developing and commercializing products to improve respiratory care, combining an experienced product development team with a growing portfolio of innovative drug delivery technologies to deliver compelling patient options for the treatment of asthma and COPD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oriel Therapeutics company profile →
Michigan Instruments
HQ: United States
Website
- Description: Provider of automated CPR devices, lung simulators, and head simulation modules for the healthcare industry; offering hands-on training, testing of respiratory care products and techniques, and advancing research and development. Its CPR chest compression machines deliver high-quality care during the treatment of cardiac arrest.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Michigan Instruments company profile →
Asmacure
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development of novel proprietary compounds targeting cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. Lead compound ASM-024 features a novel multi-functional mechanism of action with nicotinic and muscarinic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Asmacure company profile →
Owlstone Medical
HQ: United Kingdom
Website
- Description: Provider of non-invasive breath-based diagnostic tools for early disease detection. Offers the Breath Biopsy platform and OMNI solution for on-breath biomarker discovery of volatile organic compounds, research services, the ReCIVA Breath Sampler, VOC Atlas, and Collection Station, supported by a high-volume Breath Biopsy Laboratory; conducts LuCID clinical trial for early lung cancer detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Owlstone Medical company profile →
Revivant
HQ: United States
Website
- Description: Provider of medical resuscitation devices, including automated CPR devices and the patented Autopulse resuscitation device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revivant company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pulmonx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pulmonx
2.2 - Growth funds investing in similar companies to Pulmonx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pulmonx
4.2 - Public trading comparable groups for Pulmonx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →